Drugs like Ozempic now make up 5% of prescriptions in the US

US doctors write billions of prescriptions each year. During 2024, though, one type of drug stood out—“wonder drugs” known as GLP-1 agonists.

As of September, one of every 20 prescriptions written for adults was for one of these drugs, according to the health data company Truveta.

The drugs, which include Wegovy, Mounjaro, and Victoza, are used to treat diabetes, since they help generate insulin. But their popularity exploded after scientists determined the drugs tell your brain you’re not hungry. Without those hunger cues, people find they can lose 10% of their body weight, or even more.

During 2024, the drugs’ popularity hit an all-time high, according to Tricia Rodriguez, a principal applied scientist at Truveta, which studies medical records of 120 million Americans, or about a third of the population.

“Among adults, 5.4% of all prescriptions in September 2024 were for GLP-1s,” Rodriguez says. That is up from 3.5% a year earlier, in 2023, and 1% at the start of 2021.

According to Truveta’s data, people who get prescriptions for these drugs are younger, whiter, and more likely to be female. In fact, women are twice as likely as men to get a prescription.

Yet not everyone who’s prescribed the drugs ends up taking them. In fact, Rodriguez says, half the new prescriptions for obesity are going unfilled.

That’s very unusual, she says, and could be due to shortages or sticker shock over the cost of the treatment. Many insurers don ’t cover weight-loss drugs, and the out-of-pocket price can be $1,300 a month, according to USA Today.

“For most medications, prescribing rates and dispensing rates are pretty much identical,” says Rodriguez. “But for GLP-1s, we see this gap, which is really unique. It’s suggestive that people are really interested in getting these medications, but for whatever reason, they are not always able to.”

It also means the number of people taking these drugs could go higher—maybe much higher—if insurers would pay. “I don’t think that we are at the saturation point, or necessarily nearing the saturation point,” says Rodriguez, noting that around 70% of Americans are overweight or obese.

Use of the drugs may also grow dramatically if new applications are found. Companies are already exploring whether they can treat addiction, or even Alzheimer’s.

Many of the clues about those potential uses are coming directly out of people’s medical records. Because so many people are on the drugs, it means researchers like Rodriguez have a gold mine to sift through for signs of how use of the drugs is affecting other health problems.

“Because we have so many patients that are on these medications, you’re certainly likely to have a good number that also have all of these other conditions,” she says. “One of the things we’re excited about is: How can real-world data help accelerate how quickly we can understand those?”

Here are some of the new uses of GLP-1 drugs that are being explored, based on hints from real-world patient records.

Alzheimer’s disease

This year, researchers poking through records of a million people found that taking semaglutide (sold as Wegovy and Ozempic) was associated with a 40% to 70% lower chance of an Alzheimer’s diagnosis.

It’s still a guess why the drugs might be helping (or whether they really do), but large international studies are underway to follow up on the lead. Doctors are recruiting people with early Alzheimer’s in more than 30 countries who will take either a placebo or semaglutide for two years. Then we’ll see how much their dementia has progressed.

Addiction

The anecdotes are everywhere: A person on a weight-loss drug finds hunger isn’t the only craving that seems to stop.

Those are the types of clues Eli Lilly’s CEO, David Ricks, says his company will pursue next year, testing whether its GLP-1 drug, tirzepatide (called Mounjaro for diabetes treatment, and Zepbound for weight loss), could help with addiction to alcohol, nicotine, and “other things we don’t think about [as being] connected to weight.”

In comments he made in December, Ricks said the drugs might be “anti-hedonics”—meaning they counteract our hedonistic pursuit of pleasure, be it from food, alcohol, or drugs. A study this year mining digital health records found that opioid addicts taking the drugs were about half as likely to have had an overdose.

Sleep apnea

This idea goes back a ways, including to a 2015 case study of a 260-pound man with diabetes and sleep apnea. When he went on the drug liraglutide, doctors noticed that his sleeping improved.

In sleep apnea, a person gasps for air at night—it’s annoying and, with time, causes health problems.  This year, Eli Lilly published a study in the New England Journal of Medicine on its drug tirzepatide , finding that it caused a 50% decrease in breathing interruption in overweight patients with sleep apnea.

Longevity

This year, the U.S. Food and Drug Administration approved Wegovy as a cardiovascular medicine, after researchers showed the drugs could reduce heart attack and stroke in overweight people.

But that wasn’t all. The study, involving 17,000 people, found that the drug reduced the overall chance someone would die for any reason (known as “all-cause mortality”) by 19%.

That now has aging researchers paying attention. This year they named Wegovy, and drugs like it, among their the top four candidates for a general life-extension drug.

GMOs could reboot chestnut trees

Under a slice-of-heaven sky, 150 acres of rolling green hills stretch off into the distance. About a dozen people—tree enthusiasts, conservationists, research biologists, biotech entrepreneurs, and a venture capitalist in long socks and a floppy hat—have driven to this rural spot in New York state on a perfect late-July day. 

We are here to see more than 2,500 transgenic chestnut seedlings at a seed farm belonging to American Castanea, a new biotech startup. The sprouts, no higher than our knees, are samples of likely the first genetically modified trees to be considered for federal regulatory approval as a tool for ecological restoration. American Castanea’s founders, and all the others here today, hope that the American chestnut (Castanea dentata) will be the first tree species ever brought back from functional extinction—but, ideally, not the last.

Living as long as a thousand years, the American chestnut tree once dominated parts of the Eastern forest canopy, with many Native American nations relying on them for food. But by 1950, the tree had largely succumbed to a fungal blight probably introduced by Japanese chestnuts. “Now after hard work, great ideas, and decades of innovation, we have a tree and a science platform designed to make restoration possible,” American Castanea cofounder Michael Bloom told the people squinting in the sun.

As recently as last year, it seemed the 35-year effort to revive the American chestnut might grind to a halt. Now, federal regulatory approval is expected soon. And there’s millions of dollars in new funding coming in from private investors and the federal government. One conservation nonprofit is in discussions with American Castanea to plant up to a million of its chestnuts per year as soon as they’re ready and approved. 

Nothing like this has ever been tried before. But the self-­proclaimed “nutheads” believe the reintroduction of a GMO, blight-resistant American chestnut at scale could also become a model for how environmentalists can redeploy trees in general: restoring forests and shifting food production, all to combat climate change and biodiversity loss. 

“It’s a hard time to be a tree,” says Leigh Greenwood, director of the forest pest and pathogen program at the Nature Conservancy, which has been supportive of the GMO chestnut’s regulatory application. “But there’s some really interesting promise and hope.”  

Four billion trees dead 

“Charismatic megafauna” is the scientific term for species, like pandas and blue whales, that draw a disproportionate amount of love and, thus, resources. The nearly vanished American chestnut may be the most charismatic tree east of the Rockies. Because of its historical importance, fast growth, and abundant productivity of both nuts and timber, it’s drawn an exceptional amount of interest among biologists, conservationists, and a new crop of farmers. 

Trees that die back from blight occasionally resprout. Volunteer groups like the American Chestnut Cooperators’ Foundation have been working for decades to gather and crossbreed wild trees in the hopes of nudging along natural resistance to the blight. Meanwhile, the State University of New York’s College of Environmental Science and Forestry (ESF), with the support of a different group, the American Chestnut Foundation (TACF), has been pursuing genetic engineering in its labs and on its 44 wooded acres outside Syracuse. 

When ESF biologist Bill Powell and his colleagues began working with chestnut embryonic cells in 1989, it took them a decade just to optimize the growing process to make research practical. After that, researchers in the small lab inserted a wheat gene in embryos that inactivated oxalic acid, the toxin produced by the blight fungus. Gathering results on these transgenic trees takes time, because each generation has to grow for a few years before it produces the most useful data. But they eventually created a promising line, named Darling-58 after Herb Darling, a New York construction magnate who funded this research through TACF. Darling-58 was not perfect, and results varied from tree to tree and site to site. But eventually, the data showed slower infections and smaller cankers, the bulbous growths produced by the blight. 

In 2020, Darling-58 became, in all likelihood, the first genetically modified forest tree to be submitted for federal regulatory approval to the US Department of Agriculture’s Animal and Plant Health Inspection Service, the EPA, and the FDA to determine the safety of introducing it in the wild. 

“It’s a hard time to be a tree. But there’s some really interesting promise and hope.”

It is this genetically engineered strain of chestnut that American Castanea, too, is now planting and propagating in New York state, under a nonexclusive commercial license from ESF. They want to sell these trees, pending approval. And then they want to keep going, engineering ever-better chestnuts, and selling them first to enthusiasts, then to farmers, and finally to conservationists for timber, reforestation, maybe even carbon capture. 

To aid the effort, the company is looking for extraordinary wild specimens. In early 2024, it purchased an orchard that had been lovingly cultivated for three decades by a conservationist. The windy hilltop spot houses hundreds of trees, collected like stray kittens from a dozen states throughout the chestnut’s natural range. 

Most of the trees are homely and sickly with blight. They have bulging cankers, “flagging” branches sporting yellow and brown leaves, or green shoots that burst each season from their large root systems only to flop over and die back. “They make me a little sad,” admits Andrew Serazin, cofounder of American Castanea. But a few have shot up as tall as 40 feet, with only a few cankers. All these specimens have been sampled and are being analyzed. They will become the basis of a chestnut gene database that’s as complete as American Castanea can make it. 

From there, the plan is: Apply bioinformatics and AI techniques to correlate genetic signatures with specific traits. Borrow techniques developed in the cannabis industry for seedling production, cloning, and growth acceleration in high-intensity light chambers—none of which have yet been yet applied at this scale to forest trees. Develop several diverse, improved new strains of chestnut that are blight-resistant and optimized for different uses like forest restoration, nut production, and timber. Then produce seedlings at a scale previously unknown. The hope is to accelerate restoration, cutting down the time it would take resistant strains of the tree to propagate in the wild. “Tree growth takes a long time. We need to bend the curve of something that’s like a 30-year problem,” says Serazin.

The breadtree revival

The chestnut has not disappeared from the US: In fact, Americans eat some 33 million pounds of the nuts a year. These are European and Asian varieties, mostly imported. But some companies are looking to expand the cultivation of the nuts domestically. 

Among those leading the quest is a company called Breadtree Farms in upstate New York, named for a traditional nickname for the chestnut. In March, it won a $2 million grant from the USDA to build the largest organic chestnut processing facility in the US. It will be up to eight times larger than needed for its own 250 acres of trees. The company is dedicated to scaling the regional industry. “We have a list of over 100 growers that are, and will be, planting chestnut trees,” says Russell Wallack, Breadtree’s young cofounder.

Chestnuts have a nutritional profile similar to brown rice; they’re high in carbohydrates and lower in fat than other nuts. And unlike other nut trees, the chestnut “masts”—produces a large crop—every year, making it far more prolific.

That makes it a good candidate for an alternative form of agriculture dubbed agroforestry, which incorporates more trees into food cultivation. Food, agriculture, and land use together account for about one-quarter of greenhouse-gas emissions. Adding trees, whether as windbreaks between fields or as crops, could lower the sector’s carbon footprint.

Many different trees can be used this way. But Joe Fargione, science director for the Nature Conservancy’s North America region, says the chestnut is a standout candidate. “It’s great from a climate perspective, and there’s a lot of farmers that are excited about it,” he says. “Chestnuts end up being big trees that store a lot of CO₂ and have a product that can be very prolific. They have the potential to pay for themselves. We want not just environmental sustainability but economic sustainability.”

The passion for chestnut revival connects the foresters and the farmers. Farmers aren’t waiting for the GMO trees to get federal approval. They are planting existing Chinese varieties, and hybrids between American and Chinese chestnuts, which thrive in the East. Still, Fargione says that if nut cultivation is going to scale up, farmers will need reliable seed stock of genetically improved trees. 

NEGATIVES OF GREAT SMOKY MOUNTAINS NATIONAL PARK

On the other hand, those foreign orchard varieties would be considered invasives if planted in the wild. And they wouldn’t feed wildlife in the same way, says Sara Fern Fitzsimmons, chief conservation officer of the American Chestnut Foundation. “Wild turkeys prefer American chestnuts,” she says. “And the blue jay—since the American chestnut is smaller, he can fit more in his crop,” a food storage area inside a bird’s throat. For forest restoration you need American chestnuts or something as close to them as possible. That’s where the genetic engineering and crossbreeding projects will be crucial. But that path has been full of pitfalls.

Switched at birth

In late 2023, a biologist at the University of New England discovered evidence that Darling-58 was not what people thought it was. For nearly 10 years, all the data that ESF had painstakingly gathered on the strain actually pertained to a different line, Darling-54, which has its wheat gene in a different place on the genome. The promising results were all still there. The trees had simply been mislabeled that entire time. 

 A few weeks later, in December 2023, the American Chestnut Foundation suddenly announced it was withdrawing its support of ESF’s Darling tree research, citing the 54-58 mix-up, as well as what it called “disappointing performance results” for 54. 

But Andy Newhouse, director of the American Chestnut Project at SUNY ESF, says the mislabeling is not a deal-breaker. The research doesn’t “need to start from scratch,” he says. “This is correcting the record, making sure we have the appropriate label on it, and moving forward.” Newhouse says the regulatory application is ongoing (the USDA and FDA declined to comment on a pending regulatory application; the EPA did not respond to requests for comment). 

Newhouse defends the documented blight response of the trees that, we now know, are actually Darling-54.

And besides, he says, they’ve got a potentially better strain coming: the DarWin. The “Win” stands for “wound-inducible.” In these trees, the anti-blight action turns on—is induced—only when the tree’s bark is wounded, working something like an animal’s immune response. This could be more efficient than continuously expressing the anti-blight gene, the way Darling-54 does. So DarWin trees might reserve more of their energy to grow and produce nuts. 

The DarWin trees are about three years old, meaning data is still being collected. And if the Darling trees are approved for safety, it should smooth the path for a much faster approval of the DarWin trees, Newhouse says.

There was another reason, though, that TACF dropped its support of the Darling regulatory petition. In a FAQ on its website, the foundation said it was “surprised and concerned” that ESF had made a licensing deal for the Darling and DarWin trees—potentially worth millions—with a for-profit company: American Castanea.

TACF said it had been supporting the project under the assumption that the results would be available, for free, to anyone, in the “public commons.” Commercialization, it says, could make the trees more expensive for anyone who might want to plant them. Fitzsimmons wouldn’t comment further. 

The biotech boys

American Castanea’s Andrew Serazin is a Rhodes scholar whose scientific background is in tropical disease research. He rose in the ranks in global philanthropy, running million-­dollar grant competitions for the Gates Foundation, funding projects like vitamin-­enhanced “golden rice” and HIV vaccines. 

He was president of the Templeton World Charity Foundation in 2020 when it gave a “transformational” $3.2 million grant to SUNY ESF’s chestnut project. Serazin became convinced that the chestnut could be the seed of something much, much bigger. It didn’t hurt that he had a sentimental chestnut connection through his wife’s family farm in West Virginia, which dates back to the time of George Washington. 

With pests and pathogens threatening so many different species, “there’s a huge potential for there to be precision management of forests using all of the same capabilities we’ve used in human medicine,” he says. 

For that, Serazin was convinced, they needed money. Real money. Venture capital money. “I mean, really, there’s only one system that we know about that works the best for this kind of innovation, and that’s using incentives for companies to bring together these resources,” he says. 

Serazin teamed up with his friend Michael Bloom, an entrepreneur who’s sold two previous companies. They incorporated American Castanea for certification as a public benefit corporation in Delaware, pledging to balance profit with purpose and adhere to a high degree of transparency on social and environmental impact. They went to “impact investors” to sell the vision. That was part of what was going on at the seed farm on that July day; the company has $4 million in seed financing and wants to raise $7 million to $10 million more next year. 

What he’s offering investors, Serazin says, isn’t quick returns but a chance to “participate in the once-in-a-lifetime opportunity to bring back a tree species from functional extinction, and participate in this great American story.” 

What they’re proposing, over the next several decades or more, is no less than replanting the entire Eastern forest with a variety of genetically superior breeds, on the scale of millions of trees. 

It sounds, at first blush, like a sci-fi terraforming scenario. On the other hand, Leigh Greenwood, at the Nature Conservancy, says every species group of tree in the woods is threatened by climate change. Pathogens are emerging in new territories, trees are stressed by extreme weather, and the coldest winter temperatures, which used to reliably kill off all manner of forest insects and diseases at the edges of their habitats, are getting milder.

Besides chestnut blight, there’s Dutch elm disease, the emerald ash borer, butternut canker, oak wilt, and white pine blister rust. The southern pine beetle now ranges as far north as Massachusetts because of milder winters. The spongy (formerly gypsy) moth is a champion defoliator, munching enough leaves “to make an entire forest look naked in June,” says Greenwood. A new nematode that attacks leaves and buds, previously unknown to science, has emerged near the Great Lakes in the last decade. Sick and dying trees stop sequestering carbon and storing water, are prone to wildfire, and can take entire ecosystems down with them. 

“Invasive species are moving faster than biological time,” Greenwood says. “What we have to do is speed up the host trees, their natural selection. And that is an enormous task that only in very recent times have we really developed the tools in order to figure out how the heck we’re going to do that.” 

By “recent tools,” Greenwood means, more or less, what American Castanea is trying: genetic analysis and advanced horticultural techniques that allow resistant trees to be propagated and introduced into the wild more quickly. 

Greenwood is quick to say that the Nature Conservancy also supports the American Chestnut Cooperators’ Foundation, which crossbreeds wild American chestnuts for blight resistance. They are a small, all-volunteer organization with no university affiliation. They mail their crossbred chestnuts out to hobbyist landowners all over the country, and president Ed Greenwell tells me they don’t really know exactly how many are growing out there—maybe 5,000, maybe more. He has seen some that are big and healthy, he says. “We have many trees of 40-plus years of age.” 

What they don’t have is a sense of urgency. “We’re self-funded, so we could do our breeding as we choose,” says Greenwell. “Our method is tried and true, and we have no pressure to take shortcuts, like genetic modification, which theoretically could have shortened the time to get trees back in the woods.” 

The whole idea of a GMO forest tests our concept of what “nature” is. And that may just be a marker of where we are at this point in the Anthropocene.

Greenwell is not the only one to object to GMO chestnuts. In 2023, Joey Owle, then the secretary of agriculture and natural resources for the Eastern Band of Cherokee Indians, told Grist magazine that while the group was open to introducing transgenic trees on its land if necessary, it was the “last option that we would like to pursue.”

Greenwood led the writing of an expert letter, something like an amicus brief, in support of SUNY ESF’s regulatory petition for the Darling tree. She takes such objections seriously. “If we do not address the human dimensions of change, no matter how good the biological, chemical designs are,” she says, “those changes will fail.” 

That July day out at the seed farm, sitting under a tent with plates of pork barbecue, the scientists, conservationists, and businesspeople started debating how deep these GMO objections really run. Serazin said he believes that what people really hate is corporate monopoly, not the technology per se. “It’s really about the exertion of power and capital,” he said. He’s hoping that by incorporating as a public benefit corporation and making the trees widely available to conservation groups and responsible forest product and nut producers, he can convince people that American Castanea’s heart is in the right place. 

Still, others pointed out, the whole idea of a GMO forest tests our concept of what “nature” is. And that may just be a marker of where we are at this point in the Anthropocene—it’s hard to envision a future where any living creature in the ecological web can remain untouched by humans. 

That responsibility may connect us more to the past than we realize. For centuries, Native people like the Haudenosaunee Nation practiced intentional land management to improve habitat for the chestnut. When the Europeans began clearing land for farming and timber, the fast-growing tree was able to claim proportionately even more space for itself. It turns out the forest those colonists embraced—the forest dominated by chestnut trees—was no true accident of nature. It was a product of a relationship between people and chestnuts. One that continues to evolve today. 

Anya Kamenetz is a freelance reporter who writes the Substack newsletter The Golden Hour.

These companies are creating food out of thin air

Dried cells—it’s what’s for dinner. At least that’s what a new crop of biotech startups, armed with carbon-guzzling bacteria and plenty of capital, are hoping to convince us. Their claims sound too good to be true: They say they can make food out of thin air.

But that’s exactly how certain soil-dwelling bacteria work. In nature, these “autotrophic” microbes survive on a meager diet of oxygen, nitrogen, carbon dioxide, and water vapor drawn directly from the atmosphere. In the lab, they do the same, eating up waste carbon and reproducing so enthusiastically that their populations swell to fill massive fermentation tanks. Siphoned off and dehydrated, that bacterial biomass becomes a protein-rich powder that’s chock-full of nutrients and essentially infinitely renewable. 

Lisa Dyson is the founder of one of these startups, Air Protein. When she talks about the inspiration for her company, she often cites NASA research from the 1960s. Back then the agency, hoping to keep astronauts satiated on long-haul space journeys, explored the idea of growing bacterial cuisine on board before concluding, ultimately, that astronauts might not find it psychologically palatable. “Earth is actually like a spaceship,” Dyson explained in a 2016 TED Talk. “We have limited space and limited resources, and on Earth, we really do need to figure out how to recycle our carbon better.” Could these bacteria be the answer?

For now, the answer is a definite maybe. Some 25 companies worldwide have already taken up the challenge, hoping to turn abundant carbon dioxide into nutritious “air protein.” The ultimate goal of the people who work at these companies is to engineer a food source far lower in emissions than conventional farming—perhaps even one that could disrupt agriculture altogether. To do that, they’ll need to overcome some very real challenges. They’ll need to scale up production of their protein to compete commercially, and do it in a way that doesn’t create more emissions or other environmental issues. Even trickier: They’ll need to surmount the ick people may experience when contemplating a bacteria-based meal. 

Some of these companies are focused on industrial animal feed, fish meal, and pet food—products with slimmer profit margins but less exacting consumers and fewer regulatory hurdles. Human food, however, is where the real money—and impact—is. That’s why several companies, like Dyson’s Air Protein, are focused on it. In 2023 Air Protein opened its first “air farm” in San Leandro, California, a hub for the commercial food production industry, and announced a strategic development agreement with one of the largest agricultural commodity traders in the world, ADM, to collaborate on research and development and build an even larger, commercial-­scale plant. The company’s “Air Chicken” (which, to be clear, is not actual chicken) is slowly making its way toward grocery store shelves and dinner tables. But that’s only the beginning. Other companies are making progress at harnessing bacteria to spin air into protein, too—and someday soon, these microbial protein patties could be as common as veggie burgers. 

An alternative to alternative proteins

The environmental case for microbial protein is clear enough; it’s a simple calculus of arable land, energy, and mouths to feed. The global demand for protein is already at an all-time high, and with the population expected to grow to 9.7 billion by 2050, traditional agriculture will have a hard time keeping up, especially as it battles climate change, soil degradation, and disease. A growing global middle class is expected to raise levels of meat consumption, but factory-farmed meat is one of the leading drivers of greenhouse-­gas emissions. Although protein-rich alternatives like soy are far more sustainable, most of the soy grown in the world is destined for use as animal feed—not for human consumption. 

In contrast, bacterial “crops” convert carbon dioxide directly into protein, in a process that uses much less land and water. Microbial protein “farms” could operate year-round anywhere renewable electricity is cheap—even in places like Chile’s Atacama Desert, where farming is nearly impossible. That would take the strain off agricultural land—and potentially even give us the chance to return it to the wild. 

 “We are liberating food production from the constraints of agriculture,” Juha-Pekka Pitkänen, cofounder and CTO of the Finnish startup Solar Foods, explained in a recent company video. In April 2024 Solar Foods opened a demonstration factory in Vantaa, a short train ride from the Helsinki airport. It’s here, at Factory 01, that the company hopes to produce enough of its goldenrod-yellow protein powder, Solein, to prove itself viable—some 160 metric tons a year. 

Like Air Protein, Solar Foods begins its production process with naturally occurring hydrogen-­oxidizing bacteria that metabolize carbon dioxide, the way plants do. In sterile bioreactors similar to the fermentation vats used in the brewing industry, the bacteria flourish in water on a steady diet of CO₂, hydrogen, and a few additional nutrients, like nitrogen, calcium, phosphorus, and potassium. As they multiply, the bacteria thicken the water into a slurry, which is continuously siphoned off and dehydrated, creating a protein-rich powder that can be used as an ingredient in alternative meats, dairy products, and snacks.

“We are liberating food production from the constraints of agriculture.”

Juha-Pekka Pitkänen, Solar Foods

As Pitkänen explains, his research team at Finland’s state-owned VTT Technical Research Centre knew these microorganisms existed in the wild. To find a viable candidate, they narrowed down the natural conditions where one might be found, and then—as is the Finnish way—put on some hiking boots and got out there. “In Finland, you don’t have to go very far to find nature,” he says, shrugging. “You can find something useful in a ditch.”

Still, not just any old ditch bacteria would do. Their target needed to both consume carbon dioxide and continue to thrive even after it was isolated from the microbial community it coexisted with, or competed against, in nature. “We were looking for a pacifist microorganism,” Pitkänen says. “It’s quite rare.” In a wet soil-dwelling bacterium of the genus Xanthobacter,they found their match: a nontoxic, lab-friendly microbe palatable enoughto slip into myriad food preparations.

At Solar Foods’ annual summer company party this year, their in-house chef served a bright-yellow lasagna made with Solein. The powder, Pitkänen says, makes an excellent flour for fresh pasta dough and works surprisingly well as a cream replacement in ice cream. It’s rich in carotenoids, so it can taste “carroty,” and it’s full of B12 and bioavailable iron, which makes it great for vegetarians. But the product isn’t a plug-and-play replacement for milk, eggs, or even meat. Rather, it’s an ingredient like any other, competing on nutritional value, cost, and texture. The company’s main competition, Pitkänen told me, isn’t other novel proteins—it’s soy meal. 

“In the last 10 years, the whole alternative-protein landscape has changed dramatically,” says Hannah Lester, an EU-based regulatory consultant to the novel-food industry. Soy patties and bean burgers are now ubiquitous to the point of being passé; today’s cutting-edge alternative proteins are cultivated from animal cells and coaxed from specially designed microorganisms using techniques originally developed to produce vaccines and other pharmaceuticals. “Molecular farmers” tend fields of bright-pink soybeans whose genetic makeup has been doctored so that they contain proteins identical to ones pigs make. “It’s really coming to the point where companies are utilizing the most incredible technology to produce food,” she says.

A fermentation process by any other name

The space Air Protein and Solar Foods occupy is so new that language hasn’t quite coalesced around it. Some in the alternative-protein industry evocatively call it “cellular agriculture,” but it’s also referred to as “gas fermentation,” emphasizing the process, and “biomass fermentation,” emphasizing the end product. These terms are distinct from “precision fermentation,” which refers to another buzzy bioprocess that employs genetically modified yeasts, other fungi, and bacteria to produce proteins indistinguishable from their animal-­derived counterparts. Precision fermentation isn’t a new technique: The US Food and Drug Administration approved its use to produce insulin in 1982, and 80% of the rennet used in cheese is now made this way, avoiding the need to harvest the enzymes from the stomach lining of calves. 

Rather than coaxing microorganisms to produce the animal-­derived proteins we’re already familiar with, companies like Air Protein and Solar Foods are proposing that we skip the intermediary and simply eat the microbes themselves, dried into a powder. Microbial biomass made with these new fermentation technologies is fibrous, vitamin-rich, and versatile. More important, these bacteria eat carbon, require very little land and water, and need no fossil-fuel-derived fertilizers. According to a life-cycle analysis produced by the University of Helsinki and the Natural Resources Institute Finland, microbial protein is between 53% and 100% more efficient to produce than animal protein.

Of course, that’s a wide range. Finland’s electricity mix favors renewables like hydropower and wind; in a country more reliant on fossil fuels, the environmental impact of making Solein, or any microbial protein, could be much higher. Growing microbes in bulk means creating the perfect conditions for them to thrive—and, as with any industrial production process, that requires factories, equipment, and power to run the entire system. It also requires a generous supply of elements like carbon dioxide and hydrogen. 

ERIC MONGEON/MIT TECHNOLOGY REVIEW

Nearly all the world’s human-made hydrogen, a key element in the bacterial diet, comes from fossil-fuel production, and “green” hydrogen, which Solar Foods uses in its demonstration factory, comes from using renewable-powered electrolysis to split water, still an uncommon process. According to David Tze, CEO of the microbial-protein company NovoNutrients, which is currently working to branch out from industrial fish meal to human food, the segment of the microbial-protein industry powered by hydrogen is likely to set up shop wherever hydrogen is cheapest.

Carbon sources for this technology are likewise varied. If a company wants to use captured waste carbon, it will need to broker relationships with industries to connect its protein factories with those sources. Another alternative, sourcing carbon drawn from the atmosphere using direct air capture, or DAC, is still new, energy intensive, and expensive. For the time being, Air Protein uses the same commercially available carbon dioxide used in sparkling water, and while Solar Foods uses DAC for about 15% of the carbon it needs at its demonstration factory, the rest is sourced commercially. Both companies hope to adjust their carbon sources as they scale, and as DAC becomes more commercially available. 

Even if the bacteria were fed a diet of entirely captured carbon, they wouldn’t be permanently removing it from the atmosphere, since we release carbon when we digest food. Still, Tze says, “we’re giving a second life to CO₂, and allowing it to add so much more positive value to the economy.” More important, the bacteria-based products drastically reduce the emissions footprint of protein. According to a 2016 study by the World Resources Institute, producing a single ton of beef creates around 2,400 metric tons of greenhouse-gas emissions. For plant-based sources of protein, like pulses, the number is much less than 300—but for microbial proteins it may ultimately be in the single digits. “If someone can eat a bite of our product instead of a bite of anything else,” Tze says, “it could be one or three orders of magnitude difference.”

Of course, none of this works if microbial protein remains a niche industry, or if the product is too expensive for the average consumer. Even running at capacity, Solar Foods’ demonstration factory can only produce enough protein to provide the entire population of Finland with one meal a year. From a business standpoint, Pitkänen says, that’s good news: There’s plenty of room to grow. But if they hope to make a dent in the long-term sustainability of our food systems, companies like Solar Foods and Air Protein will need to scale up by orders of magnitude too. It remains to be seen if they will be able to meet that challenge—and if consumers will be ready. 

Even though both the process (fermentation) and the material (living microorganisms) are as natural as the world and as old as time, the idea of whipping air and microbes together to make dinner will strike many people as unthinkably weird. Food is cultural, after all—and especially in the US, protein is political. In interviews, Dyson takes pains to call the bacteria behind Air Protein’s process “cultures,” emphasizing the connection to traditional fermented foods like yogurt, beer, or miso. On the Solar Foods website, chic people drink yellow Solein smoothies at tasteful Nordic tables. No bacteria are pictured.

Solar Foods is still awaiting final regulatory approval in the EU and the US, but Solein is already for sale in Singapore, where it’s been whipped into chocolate gelato and hazelnut-­strawberry snack bars. If Singaporeans took issue with eating powdered bacteria, they made little show of it. When it comes to food biotechnology, the most progressive countries in the world are those with the least arable land. Singapore, which imports nearly everything, hopes to meet 30% of its own nutritional needs by 2030. Israel, a semi-arid country with limited landmass, has invested heavily in biomanufacturing, as has the Netherlands, where farmland has been heavily depleted by chemical fertilizers. But even in less constrained countries, “agriculture is on its knees because of climate change,” says Lester, the regulatory expert. “At some point, sadly, we’re just not going to be able to produce food in the traditional way. We do need alternatives. We need government support. We need fundamental policy change in how we fund food.”

This sentiment seems to be resonating in the United States. In September 2022, President Joe Biden signed an executive order to advance biomanufacturing by expanding training, streamlining regulation, and bolstering federal investment in biotechnology R&D, specifically citing “boost[ing] sustainable biomass production” as a key objective. In 2021, the Defense Advanced Research Projects Agency launched the Cornucopia program, asking four research teams—one of which includes Dyson’s company, Air Protein—to create a complete nutrition system, small enough to fit on a Humvee, that can harvest nitrogen and carbon from the air and use it to produce microbial rations in the form of shakes, bars, gels, and jerky. Microbial protein may never be deployed on long-haul space trips as NASA dreams, but it seems that the government is betting it could keep us alive on Spaceship Earth—that is, if the crew doesn’t reject it outright.

Claire L. Evans is a writer and musician exploring ecology, technology, and culture.

Two Nobel Prize winners want to cancel their own CRISPR patents in Europe

In the decade-long fight to control CRISPR, the super-tool for modifying DNA, it’s been common for lawyers to try to overturn patents held by competitors by pointing out errors or inconsistencies.

But now, in a surprise twist, the team that earned the Nobel Prize in chemistry for developing CRISPR is asking to cancel two of their own seminal patents, MIT Technology Review has learned. The decision could affect who gets to collect the lucrative licensing fees on using the technology.

­­The request to withdraw the pair of European patents, by lawyers for Nobelists Emmanuelle Charpentier and Jennifer Doudna, comes after a damaging August opinion from a European technical appeals board, which ruled that the duo’s earliest patent filing didn’t explain CRISPR well enough for other scientists to use it and doesn’t count as a proper invention.

The Nobel laureates’ lawyers say the decision is so wrong and unfair that they have no choice but to preemptively cancel their patents, a scorched-earth tactic whose aim is to prevent the unfavorable legal finding from being recorded as the reason. 

“They are trying to avoid the decision by running away from it,” says Christoph Then, founder of Testbiotech, a German nonprofit that is among those opposing the patents, who provided a copy of the technical opinion and response letter to MIT Technology Review. “We think these are some of the earliest patents and the basis of their licenses.”

Discovery of the century

CRISPR has been called the biggest biotech discovery of the century, and the battle to control its commercial applications—such as gene-altered plants, modified mice, and new medical treatments—has raged for a decade.

The dispute primarily pits Charpentier and Doudna, who were honored with the Nobel Prize in 2020 for developing the method of genome editing, against Feng Zhang, a researcher at the Broad Institute of MIT and Harvard, who claimed to have invented the tool first on his own.

Back in 2014, the Broad Institute carried out a coup de main when it managed to win, and later defend, the controlling US patent on CRISPR’s main uses. But the Nobel pair could, and often did, point to their European patents as bright points in their fight. In 2017, the University of California, Berkeley, where Doudna works, touted its first European patent as exciting, “broad,” and “precedent” setting.

After all, a region representing more than 30 countries had not only recognized the pair’s pioneering discovery; it had set a standard for other patent offices around the world. It also made the US Patent Office look like an outlier whose decisions favoring the Broad Institute might not hold up long term. A further appeal challenging the US decisions is pending in federal court.

Long-running saga

But now the European Patent Office is also saying—for different reasons—that Doudna and Charpentier can’t claim their basic invention. And that’s a finding their attorneys think is so damaging, and reached in such an unjust way, that they have no choice but to sacrifice their own patents. “The Patentees cannot be expected to expose the Nobel-prize winning invention … to the repercussions of a decision handed down under such circumstances,” says the 76–page letter sent by German attorneys on their behalf on September 20.

The chief intellectual-property attorney at the University of California, Randi Jenkins, confirmed the plan to revoke the two patents but downplayed their importance. 

“These two European patents are just another chapter in this long-running saga involving CRISPR-Cas9,” Jenkins said. “We will continue pursuing claims in Europe, and we expect those ongoing claims to have meaningful breadth and depth of coverage.”

The patents being voluntarily disavowed are EP2800811, granted in 2017, and EP3401400, granted in 2019. Jenkins added the Nobelists still share one issued CRISPR patent in Europe, EP3597749, and one that is pending. That tally doesn’t include a thicket of patent claims covering more recent research from Doudna’s Berkeley lab that were filed separately.

Freedom to operate

The cancellation of the European patents will affect a broad network of biotech companies that have bought and sold rights as they seek to achieve either commercial exclusivity to new medical treatments or what’s called “freedom to operate”—the right to pursue gene-slicing research unmolested by doubts over who really owns the technique. 

These companies include Editas Medicine, allied with the Broad Institute; Caribou Biosciences and Intellia Therapeutics in the US, both cofounded by Doudna; and Charpentier’s companies, CRISPR Therapeutics and ERS Genomics.

ERS Genomics, which is based in Dublin and calls itself “the CRISPR licensing company,” was set up in Europe specifically to collect fees from others using CRISPR. It claims to have sold nonexclusive access to its “foundational patents” to more than 150 companies, universities, and organizations who use CRISPR in their labs, manufacturing, or research products.

For example, earlier this year Laura Koivusalo, founder of a small Finnish biotech company, StemSight, agreed to a “standard fee” because her company is researching an eye treatment using stem cells that were previously edited using CRISPR.

Although not every biotech company thinks it’s necessary to pay for patent rights long before it even has a product to sell, Koivusalo decided it would be the right thing to do. “The reason we got the license was the Nordic mentality of being super honest. We asked them if we needed a license to do research, and they said yes, we did,” she says.

A slide deck from ERS available online lists the fee for small startups like hers at $15,000 a year. Koivusalo says she agreed to buy a license to the same two patents that are now being canceled. She adds: “I was not aware they were revoked. I would have expected them to give a heads-up.” 

A spokesperson for ERS Genomics said its customers still have coverage in Europe based on the Nobelists’ remaining CRISPR patent and pending application.

In the US, the Broad Institute has also been selling licenses to use CRISPR. And the fees can get big if there’s an actual product involved. That was the case last year, when Vertex Pharmaceuticals won approval to sell the first CRISPR-based treatment, for sickle-cell disease. To acquire rights under the Broad Institute’s CRISPR patents, Vertex agreed to pay $50 million on the barrelhead—and millions more in the future.

PAM problem

There’s no doubt that Charpentier and Doudna were first to publish, in a 2012 paper, how CRISPR can function as a “programmable” means of editing DNA. And their patents in Europe withstood an initial round of formal oppositions filed by lawyers.

But this August, in a separate analysis, a technical body decided that Berkeley had omitted a key detail from its earliest patent application, making it so that “the skilled person could not carry out the claimed method,” according to the finding. That is, it said, the invention wasn’t fully described or enabled.

The omission relates to a feature of DNA molecules called “protospacer adjacent motifs,” or PAMs. These features, a bit like runway landing lights, determine at what general locations in a genome the CRISPR gene scissors are able to land and make cuts, and where they can’t.

In the 76-page reply letter sent by lawyers for the Nobelists, they argue there wasn’t really any need to mention these sites, which they say were so obvious that “even undergraduate students” would have known they were needed. 

The lengthy letter leaves no doubt the Nobel team feels they’ve been wronged. In addition to disavowing the patents, the text runs on because it seeks to “make of public record the reasons for which we strongly disagree with [the] assessment on all points” and to “clearly show the incorrectness” of the decision, which, they say, “fails to recognize the nature and origin of the invention, misinterprets the common general knowledge, and additionally applies incorrect legal standards.”